Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457327 | 1.00 | KEAP1 (0.46) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL4458375 | 1.00 | KEAP1 (0.46) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL29733883 | 1.00 | KEAP1 (0.46) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL7012803 | 1.00 | KEAP1 (0.46) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL21309261 | 0.90 | KEAP1 (0.46) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL7015663 | 0.89 | KEAP1 (0.40) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL21174043 | 0.89 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL5781037 | 0.89 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL5781044 | 0.89 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL7007197 | 0.88 | KEAP1 (0.36) | KEAP1NFE2L2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776431-B1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9079922-B2 | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-19 | — | — | US | disclosed |
| EP-0952151-B1 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0992501-B1 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMA CO LTD (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| EP-0160578-B1 | 1,8-NAPHTHYRIDINE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0160578-A1 | 1,8-Naphthyridine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | OXA1L, PYM1, MRPL21 | KEAP1 2043/4885NFE2L2 3179/4885MEN1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.